HURA (TuHURA) Cumulative Company Assets

Official company branding of TuHURA Biosciences, Inc. (HURA)

This chart of total asset quotes for TuHURA Biosciences, Inc. (HURA) demonstrates the 33.19 metric. TuHURA Biosciences, Inc. (HURA) operates high-tech laboratories where cryogenic systems are being upgraded to develop immune preparations. Business resilience is supported by US centers creating treatments to prevent disease recurrence. Development relies on partnerships with specialized clinics, enabling faster verification of new cellular vaccine efficacy during testing.

TuHURA Biosciences, Inc. (HURA) Aggregate Company Assets: for the period 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for tuhurabio.com (HURA)

- market value and analyst target forecast:
Stock Price TuHURA Biosciences|HURA - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation TuHURA Biosciences, Inc.|HURA - Enterprise Value
- company book value details:
Book Value per Share TuHURA Biosciences|HURA - Company Book Value|Capitalization to Book Value Ratio tuhurabio.com|HURA - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio TuHURA Biosciences, Inc.|HURA - Long-Term Debt to Capital|Current Liabilities to Capital TuHURA Biosciences|HURA - Company Debts|Debt to Net Assets Ratio TuHURA Biosciences, Inc.|HURA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings TuHURA Biosciences|Quick Liquidity Indicator tuhurabio.com
- earnings and market multiples details:
HURA - Net Income
Basic company analysis:TuHURA (HURA)
Core merchandise of TuHURA Biosciences, Inc.

The development of anti-cancer vaccines and the protection of patents regarding tumor microenvironments require colossal capital investments in intellectual property for TuHURA Biosciences, Inc. (HURA). The current value of 33.19 is derived using a reverse method via return on assets (ROA), combining liabilities and equity. This metric assesses the total resource base necessary to complete lengthy FDA trials. By analyzing the growth of assets and resources, an investor can compare the scale of the issuer's base with its profit generation efficiency.

Key competitors

beigene.com (ONC) - Company Total Assets|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Y-mAbs Corp (YMAB)|Aggregate Company Assets Aura Biosciences, Inc.|CADL: Aggregate Asset Value|Cumulative Company Assets ARAY (Accuray)|SLS (sellaslifesciences.com) - Aggregate Asset Value|Company Total Assets ACTU (Actuate Therapeutics, Inc)|CTOR - Cumulative Company Assets|TARA: Cumulative Company Assets|FATE - Company Total Assets|aadibio.com (WHWK) - Aggregate Company Assets|TScan Therapeutics, Inc. - Aggregate Asset Value|CSBR (Champions Oncology Inc) - Company Total Assets|Company Assets XBiotech USA XBIT|Cumulative Company Assets CVM (CEL-SCI Corporation)|Aggregate Business Assets OSTX|Radiopharm Theranostics - Cumulative Company Assets|Company Total Assets Artiva Biotherapeutics Inc. ARTV|Adlai Nortye Limited - Company Total Assets|Aggregate Asset Value VERU (Veru Corporation)|TPST (Tempest Therapeutics) - Cumulative Company Assets|Xilio Therapeutics (XLO) - Company Total Assets|Aggregate Company Assets Renovaro Biosciences|MURA: Aggregate Asset Value|Company Total Assets KAPA|Company Total Assets onkuretherapeutics.com (OKUR)|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Asset Value CRIS|Apollomics Corp - Company Total Assets|THAR: Aggregate Company Assets|ADVB: Company Total Assets|GNPX - Company Total Asset Base|Aggregate Company Assets Calidi Biotherapeutics Inc.|Company Assets sunshinebiopharma.com SBFM|Aggregate Company Assets Xenetic Biosciences (XBIO)|Company Total Asset Base Salarius Pharmaceuticals Inc|Company Total Assets PPBT (Purple Biotech Corp)|AONC - Cumulative Company Assets|BeiGene, Ltd. - Company Total Assets|Company Total Asset Base checkpointtx.com CKPT|ELEV: Company Total Assets|Company Assets iCAD (ICAD)|Aggregate Company Assets Ikena Oncology Inc.|Total Business Assets NTBL (Notable Labs Corp)|Company Total Assets VIRX|Cumulative Company Assets morphosys.com MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|Ascentage Pharma Group International (AAPGV) - Company Assets